We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Reckitt Benckiser Group PLC

Latest From Reckitt Benckiser Group PLC

News

RB didn't get help from consumer perception survey to support argument that "All In One" label statement is not claim the product treats all cold and flu symptoms. Council of Better Business Bureaus' division dismisses survey as faulty but approves RB's argument. NAD attorneys conclude 15- and 6-second TV and video "superhero 'movie trailer'” ads did not include "a sufficiently proximate and prominent list of symptoms" to counter "distracting features."

News

Efforts by France to improve consumers' access to OTC medicines has fallen well short of expectations, says consumer group Familles Rurales. On average, prices are higher and vary significantly from one pharmacy to the next. Furthermore, OTCs which should be available for self-selection remain behind the counter.

News

A study commissioned by Reckitt Benckiser has found evidence suggesting that cough medicines containing antibiotics are not only ineffective against common human pathogens but are also contributing to the widely recognised problem of antimicrobial resistance. Researchers conclude that consumers should consider using non-antibiotic OTC medicines for primarily viral and self-limiting sore throat conditions instead.

News

Reckitt Benckiser was hit badly by the weak cold and flu season in the US and Europe at the start of 2019, causing its OTC sales to drop by 9%. Despite supplement sales also struggling, the firm insists it will still hit its revenue targets for the full year, with growth expected in the second half.